busulfan has been researched along with Ependymoma in 5 studies
Ependymoma: Glioma derived from EPENDYMOGLIAL CELLS that tend to present as malignant intracranial tumors in children and as benign intraspinal neoplasms in adults. It may arise from any level of the ventricular system or central canal of the spinal cord. Intracranial ependymomas most frequently originate in the FOURTH VENTRICLE and histologically are densely cellular tumors which may contain ependymal tubules and perivascular pseudorosettes. Spinal ependymomas are usually benign papillary or myxopapillary tumors. (From DeVita et al., Principles and Practice of Oncology, 5th ed, p2018; Escourolle et al., Manual of Basic Neuropathology, 2nd ed, pp28-9)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Intrathecal Spartaject Busulfan was well tolerated in children with neoplastic meningitis from brain tumors, and the recommended dose for future phase II studies is 13 mg." | 9.12 | Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004). ( Blaney, SM; Bomgaars, L; Boyett, JM; Friedman, HS; Gururangan, S; Hancock, ML; Kun, LE; Petros, WP; Phillips, PC; Poussaint, TY, 2006) |
| "Intrathecal Spartaject Busulfan was well tolerated in children with neoplastic meningitis from brain tumors, and the recommended dose for future phase II studies is 13 mg." | 5.12 | Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004). ( Blaney, SM; Bomgaars, L; Boyett, JM; Friedman, HS; Gururangan, S; Hancock, ML; Kun, LE; Petros, WP; Phillips, PC; Poussaint, TY, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (80.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gururangan, S | 1 |
| Petros, WP | 1 |
| Poussaint, TY | 1 |
| Hancock, ML | 1 |
| Phillips, PC | 1 |
| Friedman, HS | 3 |
| Bomgaars, L | 1 |
| Blaney, SM | 1 |
| Kun, LE | 1 |
| Boyett, JM | 1 |
| Grill, J | 2 |
| Kalifa, C | 2 |
| Doz, F | 1 |
| Schoepfer, C | 1 |
| Sainte-Rose, C | 1 |
| Couanet, D | 1 |
| Terrier-Lacombe, MJ | 1 |
| Valteau-Couanet, D | 1 |
| Hartmann, O | 1 |
| Graham, ML | 1 |
| Herndon, JE | 1 |
| Casey, JR | 1 |
| Chaffee, S | 1 |
| Ciocci, GH | 1 |
| Krischer, JP | 1 |
| Kurtzberg, J | 1 |
| Laughlin, MJ | 1 |
| Longee, DC | 1 |
| Olson, JF | 1 |
| Paleologus, N | 1 |
| Pennington, CN | 1 |
| Coggins, CA | 1 |
| Elion, GB | 1 |
| Houghton, PJ | 1 |
| Hare, CB | 1 |
| Keir, S | 1 |
| Colvin, OM | 1 |
| Bigner, DD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Study of Intrathecal Spartaject-Busulfan in Children With Neoplastic Meningitis[NCT00006246] | Phase 1 | 28 participants (Actual) | Interventional | 2000-11-30 | Completed | ||
| A Phase II Study of Intraventricular Methotrexate With Systemic Topotecan and Cyclophosphamide in Children With Recurrent or Progressive Malignant Brain Tumors[NCT02684071] | Phase 2 | 3 participants (Actual) | Interventional | 2016-02-29 | Terminated (stopped due to Lack of additional funding; patients (3) no longer receiving intervention.) | ||
| Phase II, Single Arm, Open Label Clinical Trial With Irinotecan in Combination With Cisplatin in Pediatric Patients With Unfavorable Prognosis Gliomas[NCT01574092] | Phase 2 | 39 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for busulfan and Ependymoma
| Article | Year |
|---|---|
Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004).
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Busulfan; Child; Child, Preschool; Choroid Ple | 2006 |
Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004).
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Busulfan; Child; Child, Preschool; Choroid Ple | 2006 |
Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004).
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Busulfan; Child; Child, Preschool; Choroid Ple | 2006 |
Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004).
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Busulfan; Child; Child, Preschool; Choroid Ple | 2006 |
A high-dose busulfan-thiotepa combination followed by autologous bone marrow transplantation in childhood recurrent ependymoma. A phase-II study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Brain Neopl | 1996 |
3 other studies available for busulfan and Ependymoma
| Article | Year |
|---|---|
High-dose chemotherapy with autologous stem-cell rescue in patients with recurrent and high-risk pediatric brain tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Brai | 1997 |
Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Busulfan; Camptothecin; Carmusti | 1998 |
High dose chemotherapy for childhood ependymona.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 1998 |